ofloxacin has been researched along with garenoxacin in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (88.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evans, CA; Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Bonner, D; Fung-Tomc, J; Gradelski, E; Kolek, B; Valera, L | 1 |
| Barrett, JF; Chaniewski, S; Frosco, M; Hooper, DC; Lawrence, LE; Ryan, B; Yang, H | 1 |
| Barrett, JF; Frosco, M; Ho, H; Lawrence, LE; Mazzucco, CE; Ryan, BM; Warr, G | 1 |
| Appelbaum, PC; Bozdogan, B; Clark, CL; Davies, TA; Dewasse, B; Jacobs, MR; Nagai, K | 1 |
| Bello, A; Kappel, EM; Shakibaei, M; Stahlmann, R | 1 |
| Frisbee-Hume, S; Ho, DH; LeBlanc, BM; Rolston, KV; Streeter, H | 1 |
| Shakibaei, M; Stahlmann, R | 1 |
| Ameyama, S; Shinmura, Y; Takahata, M | 1 |
| Piddock, L; Ricci, V | 1 |
| Almaraz, F; Baquero, F; Cantón, R; Jones, RN; Loza, E; Martín, R; Morosini, MI; Pascual, A; Perea, E; Tubau, F | 1 |
| Baumann-Wilschke, I; Bello, A; Kastner, M; Rahm, U; Stahlmann, R | 1 |
| Entenza, JM; Glauser, MP; Moreillon, P; Vouillamoz, J | 1 |
| Baltch, AL; Bopp, LH; Carpenter, AN; Halse, TA; Ritz, WJ; Smith, RP | 1 |
| Barcia-Macay, M; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Michot, JM; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Blondeau, JM; Hansen, GT | 1 |
| Gidoh, M | 1 |
| Fujioka, T; Hasegawa, M; Ikeda, F; Kobayashi, I; Kodama, M; Murakami, K; Muraoka, H; Okimoto, T; Saika, T; Takigawa, M; Tanahashi, J | 1 |
| Baba, S; Fujisawa, T; Harabuchi, Y; Ikeda, F; Kobayashi, T; Kurono, Y; Nishimura, T; Suzuki, K; Ubukata, K; Yamanaka, N | 1 |
| Fukushima, K; Hayama, Y; Ikeda, T; Nakatsubo, M; Niju, T; Noda, M; Oniki, S; Saito, Y; Tsuruta, N; Uenami, T | 1 |
1 review(s) available for ofloxacin and garenoxacin
| Article | Year |
|---|---|
Quinolone antibiotics.
Topics: | 2019 |
24 other study(ies) available for ofloxacin and garenoxacin
| Article | Year |
|---|---|
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
Topics: Animals; Biometry; Dogs; Drug Evaluation, Preclinical; Haloperidol; Haplorhini; Humans; Injections, Intravenous; Liver; Liver Circulation; Metabolic Clearance Rate; Mifepristone; Molecular Structure; Molecular Weight; Rats; Reproducibility of Results | 2006 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium leprae | 2008 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; beta-Lactams; Enterobacteriaceae; Enterococcus faecalis; Fluoroquinolones; Indoles; Kinetics; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Staphylococcus aureus; Streptococcus; Vancomycin | 2001 |
Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.
Topics: Anti-Infective Agents; Aza Compounds; DNA Topoisomerases, Type I; Fluoroquinolones; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Staphylococcus aureus | 2002 |
Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Blood Bactericidal Activity; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Indoles; Levofloxacin; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Sensitivity and Specificity; Staphylococcus aureus | 2002 |
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Streptococcus pneumoniae | 2002 |
Effects of the Des-F(6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Cartilage Diseases; Cartilage, Articular; Ciprofloxacin; Fluoroquinolones; Indoles; Knee Joint; Ofloxacin; Quinolones; Rats; Rats, Wistar | 2002 |
Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Indoles; Levofloxacin; Male; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Sensitivity and Specificity | 2002 |
Ultrastructural changes induced by the des-F(6)-quinolone garenoxacin (BMS-284756) and two fluoroquinolones in Achilles tendon from immature rats.
Topics: Achilles Tendon; Administration, Oral; Animals; Anti-Bacterial Agents; Ciprofloxacin; Female; Fluoroquinolones; Male; Microscopy, Electron; Ofloxacin; Rats; Rats, Wistar | 2003 |
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors | 2003 |
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
[Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Species Specificity; Staphylococcus aureus; Streptococcus pneumoniae | 2003 |
Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Area Under Curve; Cartilage, Articular; Ciprofloxacin; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Male; Ofloxacin; Rats; Rats, Wistar; Specific Pathogen-Free Organisms | 2004 |
Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Endocarditis, Bacterial; Floxacillin; Fluoroquinolones; Infusions, Intravenous; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Rats; Staphylococcal Infections; Streptococcal Infections; Vancomycin; Viridans Streptococci | 2004 |
In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA.
Topics: Anti-Infective Agents; Chlamydia Infections; Chlamydophila pneumoniae; Databases, Genetic; DNA, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycoplasma; Ofloxacin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Ribosomal, 16S | 2004 |
Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line, Tumor; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Listeria monocytogenes; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Time Factors | 2005 |
Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Ciprofloxacin; Fluoroquinolones; Heat-Shock Response; Humans; Kinetics; Levofloxacin; Macrophages; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2005 |
Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Urinary Tract Infections | 2005 |
[In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
Topics: Animals; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Leprostatic Agents; Levofloxacin; Mice; Mice, Inbred BALB C; Mice, Nude; Moxifloxacin; Mycobacterium leprae; Ofloxacin; Quinolines; Rifampin | 2007 |
Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations.
Topics: Anti-Bacterial Agents; DNA Gyrase; Fluoroquinolones; Helicobacter pylori; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin | 2009 |
[Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mutation; Ofloxacin; Otorhinolaryngologic Diseases; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2010 |
Anaphylaxis due to intravenous levofloxacin with tolerance to garenoxacin.
Topics: Adult; Anaphylaxis; Anti-Bacterial Agents; Cross Reactions; Drug Hypersensitivity; Fluoroquinolones; Humans; Injections, Intravenous; Levofloxacin; Male; Ofloxacin; Pneumonia, Mycoplasma; Skin Tests | 2012 |